Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8691338 | 0.94 | ELANE (0.46) | ELANETACR1FKBP4LMNAXIAP | |
| SCHEMBL8010107 | 0.90 | FKBP4 (0.46) | ELANETACR1FKBP4LMNAMMP2 | |
| SCHEMBL1257864 | 0.88 | LMNA (0.53) | TACR1LMNAMMP2MMP9MAPK1 | |
| SCHEMBL5501048 | 0.86 | TACR1 (0.47) | TACR1FKBP4LMNAMMP2TRPV1 | |
| SCHEMBL6523783 | 0.85 | CMA1 (0.48) | ELANE | |
| SCHEMBL7277525 | 0.85 | TACR1 (0.43) | ELANETACR1FKBP4LMNAMMP2 | |
| SCHEMBL3244930 | 0.84 | ELANE (0.43) | ELANETACR1FKBP4LMNAXIAP | |
| SCHEMBL3667052 | 0.84 | FKBP4 (0.58) | TACR1FKBP4 | |
| SCHEMBL27824844 | 0.83 | LMNA (0.48) | TACR1LMNAMMP2MMP9MAPK1 | |
| SCHEMBL1296384 | 0.83 | LMNA (0.48) | TACR1LMNAMMP2MMP9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709365-A2 | FORMULATIONS OF PECTOLINARIGENIN | Debut Biotechnology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4037687-B1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | MOLECULAR SKIN THERAPEUTICS INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12281123-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | MOLECULAR SKIN THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2025035070-A1 | FORMULATIONS OF ERIODICTYOL | Debut Biotechnology, Inc. (US) | 2025-02-13 | — | — | WO | disclosed |
| CN-114615984-B | Benzoxazinone compounds as dual KLK5/7 inhibitors | 分子皮肤治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2024233739-A2 | FORMULATIONS OF PECTOLINARIGENIN | Debut Biotechnology, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024233754-A2 | FORMULATIONS OF 4,6,4'-TRIHYDROXY-3'- METHOXYAURONE | Debut Biotechnology, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024233743-A2 | FORMULATIONS OF CALYCOSIN | Debut Biotechnology, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024233751-A2 | FORMULATIONS OF CARDAMONIN | Debut Biotechnology, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240067658-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | ML Bio Solutions Inc. | 2024-02-29 | — | — | US | disclosed |
| CN-113038949-B | Neutrophil inflammation inhibitor and application thereof | 长庚学校长庚科技大学 | 2023-07-14 | — | — | CN | disclosed |
| US-11643420-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | MOLECULAR SKIN THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-4037687-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | Molecular Skin Therapeutics, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114615984-A | Benzoxazinone compounds as KLK5/7 dual inhibitors | 分子皮肤治疗公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2012148527-A2 | BIOACTIVE BOTANICAL COSMETIC COMPOSITIONS AND PROCESSES FOR THEIR PRODUCTION | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2012-11-01 | — | — | WO | disclosed |
| EP-2203059-A1 | METHOD OF TREATING INHERITED SEVERE NEUTROPENIA | Merck Sharp & Dohme Corp. (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009035541-A1 | METHOD OF TREATING INHERITED SEVERE NEUTROPENIA | MERCK & CO., INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281123-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | KLK5, KLK1, KLK2 | ELANE 300/4885TACR1 3719/4885FKBP4 1580/4885 |
| US-11643420-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | KLK5, KLK1, KLK2 | ELANE 300/4885TACR1 3719/4885FKBP4 1580/4885 |
| US-20240067658-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | KLK5, KLK1, KLK2 | ELANE 300/4885TACR1 3719/4885FKBP4 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.